These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14694167)

  • 21. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial.
    Laville M;
    Acta Diabetol; 2004 Mar; 41 Suppl 1():S18-22. PubMed ID: 15103544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
    Jones M; Schenkel B; Just J
    Int J Cardiol; 2005 Apr; 100(2):253-65. PubMed ID: 15823633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
    Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.
    Foley RN; Curtis BM; Randell EW; Parfrey PS
    Clin J Am Soc Nephrol; 2010 May; 5(5):805-13. PubMed ID: 20378644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance.
    Pappas KD; Gouva CD; Katopodis KP; Nikolopoulos PM; Korantzopoulos PG; Michalis LK; Goudevenos JA; Siamopoulos KC
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):37-44. PubMed ID: 18095148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
    Crawford J; Robert F; Perry MC; Belani C; Williams D;
    J Thorac Oncol; 2007 Mar; 2(3):210-20. PubMed ID: 17410044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Jones M; Ibels L; Schenkel B; Zagari M
    Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
    Drüeke TB; Locatelli F; Clyne N; Eckardt KU; Macdougall IC; Tsakiris D; Burger HU; Scherhag A;
    N Engl J Med; 2006 Nov; 355(20):2071-84. PubMed ID: 17108342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of early correction of anemia on the progression of CKD.
    Rossert J; Levin A; Roger SD; Hörl WH; Fouqueray B; Gassmann-Mayer C; Frei D; McClellan WM
    Am J Kidney Dis; 2006 May; 47(5):738-50. PubMed ID: 16632012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
    Eschbach JW
    J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.